Jump to Main Content
MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis
- Wo, Xiaoman, Han, Dong, Sun, Haiming, Liu, Yang, Meng, Xiangning, Bai, Jing, Chen, Feng, Yu, Yang, Jin, Yan, Fu, Songbin
- Journal of genetics and genomics 2011 v.38 no.8 pp. 341-350
- confidence interval, genes, genotype, meta-analysis, odds ratio, promoter regions, prostatic neoplasms, risk
- The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models (GG vs. TT: OR, 1.123; 95% CI, 1.056–1.193; GG/GT vs. TT: OR, 1.028; 95% CI, 1.006–1.050). In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital- /population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer (GG vs. TT: OR, 0.606; 95% CI, 0.407–0.903; GG/GT vs. TT: OR, 0.748; 95% CI, 0.579–0.968). In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.